Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Subscribe To Our Newsletter & Stay Updated
